327 related articles for article (PubMed ID: 22692562)
1. Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets.
Nagy JA; Dvorak HF
Clin Exp Metastasis; 2012 Oct; 29(7):657-62. PubMed ID: 22692562
[TBL] [Abstract][Full Text] [Related]
2. Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy.
Sitohy B; Nagy JA; Jaminet SC; Dvorak HF
Cancer Res; 2011 Nov; 71(22):7021-8. PubMed ID: 21937680
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of the tumor vasculature.
Nagy JA; Chang SH; Shih SC; Dvorak AM; Dvorak HF
Semin Thromb Hemost; 2010 Apr; 36(3):321-31. PubMed ID: 20490982
[TBL] [Abstract][Full Text] [Related]
4. Anti-VEGF/VEGFR therapy for cancer: reassessing the target.
Sitohy B; Nagy JA; Dvorak HF
Cancer Res; 2012 Apr; 72(8):1909-14. PubMed ID: 22508695
[TBL] [Abstract][Full Text] [Related]
5. Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy.
Dvorak HF
Cancer J; 2015; 21(4):237-43. PubMed ID: 26222073
[TBL] [Abstract][Full Text] [Related]
6. Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels.
Sitohy B; Chang S; Sciuto TE; Masse E; Shen M; Kang PM; Jaminet SC; Benjamin LE; Bhatt RS; Dvorak AM; Nagy JA; Dvorak HF
Am J Pathol; 2017 Oct; 187(10):2337-2347. PubMed ID: 28736316
[TBL] [Abstract][Full Text] [Related]
7. Tumor angiogenesis and anti-angiogenic therapies.
Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
[TBL] [Abstract][Full Text] [Related]
8. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
9. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
Hu-Lowe DD; Chen E; Zhang L; Watson KD; Mancuso P; Lappin P; Wickman G; Chen JH; Wang J; Jiang X; Amundson K; Simon R; Erbersdobler A; Bergqvist S; Feng Z; Swanson TA; Simmons BH; Lippincott J; Casperson GF; Levin WJ; Stampino CG; Shalinsky DR; Ferrara KW; Fiedler W; Bertolini F
Cancer Res; 2011 Feb; 71(4):1362-73. PubMed ID: 21212415
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab attenuates VEGF-induced angiogenesis and vascular malformations in the adult mouse brain.
Walker EJ; Su H; Shen F; Degos V; Amend G; Jun K; Young WL
Stroke; 2012 Jul; 43(7):1925-30. PubMed ID: 22569934
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor inhibitors in colon cancer.
Díaz-Rubio E
Adv Exp Med Biol; 2006; 587():251-75. PubMed ID: 17163170
[TBL] [Abstract][Full Text] [Related]
12. Anti-Angiogenics: Current Situation and Future Perspectives.
Zirlik K; Duyster J
Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
14. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
15. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
[TBL] [Abstract][Full Text] [Related]
17. [Tumor angiogenesis: new approaches to cancer therapy].
Marmé D
Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
[TBL] [Abstract][Full Text] [Related]
18. Complementary actions of dopamine D2 receptor agonist and anti-vegf therapy on tumoral vessel normalization in a transgenic mouse model.
Chauvet N; Romanò N; Lafont C; Guillou A; Galibert E; Bonnefont X; Le Tissier P; Fedele M; Fusco A; Mollard P; Coutry N
Int J Cancer; 2017 May; 140(9):2150-2161. PubMed ID: 28152577
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract][Full Text] [Related]
20. Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis.
Blankenberg FG; Levashova Z; Goris MG; Hamby CV; Backer MV; Backer JM
J Nucl Med; 2011 Oct; 52(10):1630-7. PubMed ID: 21890879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]